AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Efficacy and Safety of Ultrasound-Guided Pharmacopuncture as an Adjunctive Therapy in Inpatients With Post-Traffic Accident Tension-Type Headache

RecruitingNAAges 19 Years - 69 YearsAllJaseng Medical Foundation
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to reveal the effectiveness and safety of ultrasound-guided pharmacopuncture for patients with tension-type headache caused by a traffic accident. It is a pragmatic clinical study to confirm the comparative effectiveness by comparing the strategy of combining ultrasound-guided pharmacopuncture in parallel with the strategy of treating with integrative Korean medicine treatment, which is an existing treatment method.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients hospitalized for the treatment of traffic accidents with tension-type headache originating from a traffic accident within 14 days of onset. * Patients with a headache NRS (Numeric Rating Scale) score of 5 or higher. * Patients diagnosed with tension-type headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria: * Headache exhibiting at least two of the following characteristics: * Bilateral location * Pressing or tightening (non-pulsating) quality * Mild or moderate intensity * Not aggravated by routine physical activity such as walking or climbing stairs * Fulfilling both of the following conditions: * No nausea or vomiting * No more than one of photophobia or phonophobia * Patients aged between 19 and 69 years old (aged 19 to less than 70 years). * Participants who voluntarily decide to participate, fully understand the details of the clinical study, agree to follow precautions, and provide written informed consent. Exclusion Criteria: * Patients diagnosed with specific serious medical conditions requiring surgical management rather than conservative treatment (e.g., acute fracture, dislocation, complete ligament rupture, etc.). * Cases where the cause of pain originates from conditions other than tension-type headache (e.g., intracerebral hemorrhage, cerebral infarction, hypertension, ocular diseases, drug-induced headache, etc.). * Cases where surgical intervention is required due to suspected acute cervical spine fracture, herniated cervical disc, or spinal ligament injury. * Patients diagnosed with primary headache disorders other than tension-type headache, such as migraine or cluster headache. * Patients with other acute diseases (e.g., stroke, myocardial infarction, kidney disease, diabetic neuropathy, dementia, epilepsy, etc.) that may interfere with the treatment effect or interpretation of study results. * Patients currently taking steroids, immunosuppressants, psychiatric medications, or other drugs that may affect the study findings. * Cases where pharmacopuncture treatment is inadequate or unsafe: patients with hemorrhagic diseases, those receiving anticoagulant therapy, or severe diabetic patients with a risk of infection. * Patients who have taken medications that may affect pain, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or have received pharmacopuncture or physical therapy within the past 1 week. * Pregnant women, women who are planning to become pregnant, or nursing mothers. * Patients within 3 months following head or neck-related surgery. * Patients who finished participating in another clinical study less than 1 month prior, or who plan to participate in another clinical study during the study and follow-up period within 6 months from the date of selection. * Cases where it is difficult to obtain written informed consent for participation. * Other cases where the investigator deems the candidate unsuitable for participation in the clinical study.
๐Ÿ’Š

What it tests

  • Cervicocranial ultrasound-guided pharmacopuncture
  • Oriental medicine integrated treatment
๐Ÿ“

Where

1 site
Daejeon Jaseng Hospital of Korean Medicine, Daejeon
Daejeon, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy